Stock Screener App

무료 -

설치하다

13.08

0.38% 0.05

Agomab Therapeutics Nv Adr (AGMB)

개요 뉴스 가격 이력 토론 예측

Agomab Therapeutics Nv Adr 주식(AGMB)의 최신 뉴스

Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail

AGMBAgomAb Therapeutics NV ADR Short Interest - Finviz

AgomAb Therapeutics NV ADR Actuals & Estimates (NASDAQ:AGMB) - TradingView

AGMB Forecast — Price Target — Prediction for 2027 - TradingView

Agomab announces Phase 2b study design for Crohn’s disease drug - Investing.com

Form 6K Agomab Therapeutics Nv For: 23 June By Investing.com - Investing.com India

This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday - Sahm

This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Sahm

H.C. Wainwright initiates Agomab stock coverage with buy rating - Investing.com

Agomab Announces Results of Annual General Meeting - GlobeNewswire Inc.

Why AgomAb (AGMB) is a smarter play than most realize (Drops Hard) 2026-05-08BPI Bear Correction - The Legal Advocate

Agomab Posts 2025 Loss, Fortifies Cash After IPO and Targets Key 2026 Trial Milestones - The Globe and Mail

AgomAb (NASDAQ: AGMB) posts €62.5m loss and funds operations into 2029 - Stock Titan

AGMB Technical Analysis | Trend, Signals & Chart Patterns | AGOMAB THERAPEUTICS NV (NASDAQ:AGMB) - ChartMill

United Health Group, Viacom among market cap stock movers on Tuesday - Investing.com

Reviewing Prime Medicine (NASDAQ:PRME) and AgomAb Therapeutics (NASDAQ:AGMB) - Defense World

Agomab receives U.S. patent for lung fibrosis drug candidate By Investing.com - Investing.com India

Agomab receives U.S. patent for lung fibrosis drug candidate - Investing.com

Total equity of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView

Total liabilities of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView

Total liabilities & shareholders' equities of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView

Total debt of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView

AgomAb Therapeutics NV ADR Balance Sheet – DUS:M5E - TradingView

AgomAb Therapeutics NV ADR Cash Flow – DUS:M5E - TradingView

EBITDA per share of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView

AgomAb Therapeutics NV ADR Income Statement – DUS:M5E - TradingView

AgomAb Therapeutics NV ADR Earnings and Revenue – DUS:M5E - TradingView

Basic earnings per share (basic EPS) of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView

Free float of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView

Net income of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView

This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - Sahm

Total common shares outstanding of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Tangible book value per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Debt to assets ratio of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Cash per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Net current asset value per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Enterprise value to EBITDA ratio of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

EBITDA margin % of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

AgomAb Therapeutics NV ADR Cash Flow – TRADEGATE:M5E - TradingView

AgomAb Therapeutics NV ADR Balance Sheet – TRADEGATE:M5E - TradingView

EBITDA of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Diluted earnings per share (diluted EPS) of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Non-operating income (total) of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

AgomAb Therapeutics NV ADR Financial Statements – TRADEGATE:M5E - TradingView

Diluted net income available to common stockholders of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

AgomAb Therapeutics NV ADR Revenue Breakdown – TRADEGATE:M5E - TradingView

AgomAb Therapeutics NV ADR Statistics – TRADEGATE:M5E - TradingView

Gross profit of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Net income before discontinued operations of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Operating income of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Total revenue of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Non-controlling/minority interest of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

AgomAb Therapeutics NV ADR Income Statement – TRADEGATE:M5E - TradingView

AgomAb Therapeutics NV ADR Earnings and Revenue – TRADEGATE:M5E - TradingView

Free float of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

What is the current Price Target and Forecast for AgomAb Therapeutics NV (AGMB) - Zacks Investment Research

Agomab closes $200 million IPO on NASDAQ - Investing.com India

Agomab closes $200 million IPO on NASDAQ By Investing.com - Investing.com Nigeria

EQT Life Sciences-Backed AgomAb Falls After $200 Million IPO - livemint.com

Agomab Therapeutics opens below IPO price in Nasdaq debut By Investing.com - Investing.com Canada

RPRX

$56.43

2.64%

INSM

$115.61

2.24%

ROIV

$35.97

2.28%

MRNA

$68.27

10.83%

ONC

$298.70

1.36%

RVMD

$186.88

2.22%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기 | MarketWatch에서 열기 | EDGAR에서 열기 | 로이터에서 공개